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Background: Optical coherence tomography (OCT) is increasingly used in the cath-
eterization laboratory. Previous smaller studies have reported the safety of OCT in
different clinical settings, however large datasets are still lacking. We report safety of
intracoronary Fourier Domain OCT (FD-OCT) imaging in a real world series of
consecutive patients that underwent OCT during coronary catheterization in our center.
Methods: Prospective, single center registry in patients scheduled for coronary
angiography or intervention (n¼1,157) undergoing intracoronary OCT between April
2008 and December 2013. In total, 3,076 pullbacks were performed with 7 different
OCT-systems. Any complication that occurred during or within the immediate 24-
hour period following OCT examination was registered and classiﬁed as either pro-
cedure or OCT-related event (self-limiting, requiring action or major adverse event).
FD-OCT was performed during continuous intracoronary ﬂushing with x-ray contrast
through the guide catheter using an injector pump (ﬂow rate 3-4ml/sec). A bolus of
intracoronary nitroglycerine was routinely administered before introduction of the
OCT catheter into the coronary artery.
Results: OCT was performed in an unselected group of patients with the only
exclusion criteria of acute life-threatening hemodynamic instability and extensive
calciﬁcations (Table 1). OCT imaging was successfully performed in all patients.
There were 47 angiographic adverse ﬁndings related to the catheterization and/or PCI
procedure and no major adverse cardiac events were related to OCT imaging. Nine
events were directly related to OCT imaging, but all were considered self-limiting or
easily treatable. The event rate was 0.8% per patient and 0.3% per pullback.Table 1. Patient characteristics and complication overview. *All transient.
LAD: left anterior descending artery; LCX: left circumﬂex artery; RCA: right
coronary artery.
Indications for
catheterization
n ¼ 1,157
(%) Imaged vessel
Pullbacks,
n ¼ 3,076 (%)
Stable angina 435 (37.6) LAD 1482 (48.1)
Unstable angina 180 (15.6) Cx 576 (18.7)
Myocardial infarction 379 (32.8) RCA 846 (27.5)
Follow-up 125 (10.8) Other 172 (5.6)
Other 38 (3.3)
Procedure related
complications
OCT related complications*
Dissection 36 (3.1) ST elevation 3 (0.3)
Perforation 0 Bradycardia 1 (0.1)
Vessel occlusion 0 Dissection 0
Sidebranch occlusion 5 (0.4) Perforation 0
No reﬂow (including
TIMI-II ﬂow)
6 (0.5) Coronary spasm 4 (0.3)
Thrombus formation 0
Air embolism 1 (0.1)
Arrhythmias 0Conclusions: OCT is safe and feasible in unselected patients. Imaging related events
were scarce, self-limiting or easily treatable, and transient.
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Background: Long-term vessel response after biodegradable polymer biolimus-
eluting stents (BES) implantation remains unclear. We sought to evaluate the vascular
response of biodegradable polymer BES at 5 years after stent implantation usingB112 JACC Vol 64/11/Suppl B joptical coherence tomography (OCT) as compared with that of durable polymer
sirolimus-eluting stents (SES) and bare-metal stents (BMS).
Methods: Five-year follow-up OCT was performed in 30 patients with 33 stents (10
with 12 BES; 10 with 11 SES; 10 with 10 BMS). Quantitative parameters and
qualitative characteristics of the neointima were evaluated.
Results: A total of 5,178 struts (BES, n¼2,056; SES, n¼1,410; BMS, n¼1,712) were
analyzed. The percentage of uncovered struts was 0.7% of the BES group, which was
signiﬁcantly lower and higher than that of the SES and BMS groups (3.8% and 0.0%,
P< 0.001, respectively). Malapposed struts in the BES group were signiﬁcantly lower
than the SES group (0.2% vs. 2.4%, P< 0.001), whereas they did not differ from the
BMS group (0.2% vs. 0.0%, P¼0.39). Cross-sectional qualitative analysis of neo-
intimal tissue showed that the frequency of lipid-laden neointima was signiﬁcantly
lower in the BES group than the SES group (6.3% vs. 13.9%, P¼0.031), and similar to
the BMS group (6.3% vs. 5.2%, P¼0.83).
Conclusions: Biodegradable polymer BES shows a favorable vascular response
compared to SES, but slightly different response from BMS at 5-year follow-up. The
observed frequency of in-stent neoatherosclerosis within BES is similar to BMS and
signiﬁcantly lower than SES, which may be due to the difference of polymer between
BES and SES.
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Background: The beneﬁts of statin treatment in ischemic heart disease and its ability
to induce plaque regression assessed by intravascular ultrasound (IVUS) are well
established. Further reduction in levels of Low Density Lipoproteins (LDL) can be
obtained by additional treatment with the cholesterol absorption inhibitor Ezetimibe,
but its clinical signiﬁcance has yet to be determined. The aim of the OCTIVUS study
was to examine the optical coherence tomography (OCT) and intravascular ultrasound
(IVUS) with iMap changes in plaque composition and volume of atorvastatin, as
monotherapy and in combination with Ezetimibe, in patients with ST-segment
elevation myocardial infarction.
Methods: The OCTIVUS trial (ClinicalTrials.gov ID: NCT01385631) is a single
center prospective double blinded randomized trial designed to determine the change
in plaque volume and composition using IVUS with iMap and OCT. Statin naïve
patients with STEMI were randomized to receive atorvastatin (80 mg) as monotherapy
or atorvastatin 80 mg in combination with Ezetimibe 10 mg, and underwent IVUS
with iMap and OCT at baseline (n ¼ 86) and study completion at 12 months (n ¼ 82).
Angiographic inclusion criteria was the presence of a >20% and < 50% plaque in a
non-culprit vessel.
Results: The overall study cohort is as follows: Mean age: 56.2 years  10.1 years,
male gender: n ¼ 74 (86%), Mean BMI: 27.7  4.5 kg/m2, family history of ischemic
heart disease: n ¼ 41 (47.7%), hypertension: n ¼ 19 (22.1%), smokers: n ¼ 48
(55.8%) and diabetes mellitus: n ¼ 2 (82.3%). The distribution between groups cannot
be assessed until unblinding. Endpoint results are presented at TCT 2014.
Conclusions: The high resolution of OCT in conjunction with the histologic classi-
ﬁcation by iMap enables a more detailed assessment of vulnerable plaque features
such as ﬁbroartheroma cap thickness, necrotic core and the presence of macrophages
and cholesterol crystals. An improvement in these parameters might be a useful in-
dicator of the possible clinical beneﬁts in real world patient treatment.
TCT-385
Association of Target Lesion Coronary Calciﬁcation with Stent Expansion and
Eccentricity: An Optical Coherence Tomography Study
Yuhei Kobayashi1, Teruyoshi Kume1, Ryotaro Yamada1, Yukari Kobayashi1,
Kenzo Fukuhara1, Terumasa Koyama1, Yoji Neishi1, Hiroyuki Okura1
1Kawasaki medical school, Kurashiki, Japan
Background: Although target lesion calciﬁcation negatively affects stent expansion,
previous IVUS studies failed to demonstrate a relationship between stent expansion
and the amount of coronary calcium. Optical coherence tomography (OCT) offers
better quantitative assessment of coronary calcium than IVUS, and therefore may have
potential to predict stent expansion.
Methods: 51 de novo native coronary artery lesions treated by single 2nd generation
drug-eluting stent (DES) were enrolled. Prior to intervention, arc and area of calcium
at the largest calciﬁcation site were measured using OCT. After stent implantation,
OCT imaging was repeated to assess minimum stent diameter and area (MSD and
MSA). Stent expansion was deﬁned as MSD (or MSA) divided by the values pre-
dicted by the compliance charts. Stent eccentricity was also calculated (Figure). Pa-
tients were divided into 4 groups according to the median values of arc and area of
calcium.
Results: Arc of calcium was associated with stent expansion deﬁned by MSD
(p< 0.01) and MSA (p¼0.02). Area of calcium was also associated with stent
expansion deﬁned by MSD (p¼0.01) but not statistically signiﬁcant with MSASeptember 13–17, 2014 j TCT Abstracts/Imaging Intravascular - OCT
